The FDA has approved a new treatment option that is the first drug approved by the FDA specifically for the treatment of postpartum depression in adult women.
The FDA Psychopharmacologic Drug Advisory Committee and Drug Safety and Risk Management Advisory Committee jointly voted on the benefit-risk profile of esketamine nasal spray for the treatment of adults...
